Replies to post #57495 on Ayala Pharmaceuticals Inc (ADXS)

[Keithz]

The next update on shareholders should be telling......

[Chemist823]

Manipulation only works when you have a catalyst at the start or during relatively low volume periods. A deal after the meeting with substantial upfront money could cause return to double digits, not through manipulation but through strong buying. Not to say there will be no manipulation bringing it higher than it might go otherwise. In other words manipulators don't have 100% control of stock price 100% of the time. News vacuum, negative or positive catalyst provides opportunity to be additive to the movement in either direction.

[cdiddy01]

So the lack of buying and interest in the company/science is due to a group or "consortium" of funds, in tandem, controlling the share price through manipulation and keeping others out? In addition, our only salvation is to get them to stop? Wouldn't adxs have reasonable insight into this and seek legal council, or is this all grey area?

This also begs the question, if true, maybe it is time to toss the keys to someone else before additional damage is done. Dilution at 2 is almost beyond the pale. The science should be recognized by BP for what it is...

[ignatiusrielly35]

Right on, Gantor. It amazes me that anyone denies that this stock has been highly manipulated.

[gbrown6332]

Fan of your posts Gantor. I suspect your estimate that some entity has made $100M is on the low side.

Adage made their initial investment in ADXS in December 2014. Remains to be seen if Dan found a financial savior or sold his soul to the Devil for $7.50 a share at the time, but let’s review the roller coaster that followed.

ADXS SP was about $5.60 and the market cap was roughly $150M in December ‘14 when the share price headed north after Adage participation was announced with great fanfare. The SP took off. It had already hit $23 on April 24, 2015 but had fallen back to $17 on May 1st so Adage goosed the SP again in May when they bought another 500,000 shares for $19. The effect again was immediate as the SP shot straight up to close at $28.77 on June 1st, 2015 after flirting with $30.

The successful, some might suggest engineered, runup took just over six months. ADXS market cap was $890M give or take on June 1st ‘15 based on 31M outstanding shares.

We’re now approaching three years of the drip, drip, drip that followed as we’ve watched an estimated $790M in market cap evaporate, including the short Amgen inspired recovery. Tough to pin the decline on ADXS scientific prospects as they’re generally much further along now than the end of 2014. Can’t really blame the questionable FDA hold as it was remedied by simply tweaking patient eligibility criteria. Management is very average and a little greedy, but aside from financial ineptness, they’ve established valid partnerships and slowly advanced the trials.

The financial predator at work here appears to be hiding in plain sight.

G.B.